A Milestone Moment for ACD/Labs and Our Community
Revvity Signals’ planned acquisition of ACD/Labs brings together two leading scientific software portfolios, promising deeper integration, expanded workflows, and enhanced data, automation, and analytical capabilities to better support chemistry, pharmaceutical R&D, and end-to-end scientific decision-making.
Advanced Data Analysis of Peptide LC-MS Spectra through In Silico Fragmentation
Highlighting a vendor-neutral in-silico fragmentation workflow that automates peptide MS/MS interpretation; improving fragment assignment accuracy, enabling structural visualization, distinguishing isomers, and streamlining reporting—which centralizes data processing across multiple instrument platforms.
Spiromastixone Z4
According to Crew’s rule, if the ratio of the number of hydrogen atoms to the number of skeletal atoms in a molecule is less than one, then significant difficulties typically arise in elucidating the structure using one- and two-dimensional NMR spectroscopy. It was interesting to see how ACD/Structure Elucidator handles this problem in an “ab initio” mode with Spiromastixone Z4 (molecular formula C20H19Br3O5).
ACD/Labs Announces Version 2025 of Software on Its Spectrus® & Percepta® Platforms
Latest Spectrus applications offer deeper integrations, improvement to low code/no code automation, expansion of data import/export, and enhanced analytical data processing and interpretation. Percepta delivers improved prediction accuracy for several models.
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
ACD/Labs is pleased to share that Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs. The acquisition will expand the breadth and depth of Revvity Signals’ solutions and bridge the gap between analytical data and actionable insights.
Spectroscopic Workflow Automation & Data Management…Going Paperless
Á. Szigetvári, Gedeon RichterDiscover how Gedeon Richter is automating spectroscopic workflows and managing analytical data end-to-end—going paperless, improving traceability, and accelerating method development in R&D.